Role of LMO7 in atherosclerosis
LMO7 在动脉粥样硬化中的作用
基本信息
- 批准号:10224324
- 负责人:
- 金额:$ 56.8万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-08-01 至 2024-07-31
- 项目状态:已结题
- 来源:
- 关键词:Apolipoprotein EApoptosisArterial Fatty StreakArteriesAtherosclerosisBlood CirculationCardiovascular DiseasesCarotid EndarterectomyCellsCharacteristicsCholesterolCollagenDataDependenceEventExhibitsExtracellular MatrixFeedbackFunctional disorderGene ExpressionGenesHigh Fat DietHumanIn VitroInflammationInflammatoryInvestmentsKnock-outKnockout MiceLIM DomainLIM Domain ProteinLesionLipidsMapsMetalloproteasesMethodsModelingMolecularMorbidity - disease rateMorphologyMusMyocardial InfarctionNecrosisPathway interactionsPeripheral Vascular DiseasesPhenotypePlayProteinsResolutionRoleRuptureSamplingSignal PathwaySignal TransductionSmooth MuscleSmooth Muscle MyocytesSpecimenStainsStrokeTestingTherapeuticThickThinnessVascular Smooth Muscleatheroprotectiveatherosclerotic plaque rupturebiobankcoronary plaquein vivoinsightloss of functionmRNA Expressionmolecular imagingmortalitynovelpreventsingle-cell RNA sequencingtranscription factortransdifferentiationvascular injurywound healing
项目摘要
Role of LMO7 in atherosclerosis Atherosclerosis is a major cause of cardiovascular disease morbidity and
mortality, including myocardial infarction (MI), stroke, and peripheral vascular disease. As plaque rupture is a
key factor in atherothrombotic events, understanding the determinants of plaque stability is critical. The
underlying molecular mechanisms are poorly understood, but thin cap fibroatheromas, characterized by
inflammation, matrix metalloprotease (MMP) activity, large necrotic cores, and thin fibrous caps, are considered
more vulnerable to rupture. Vascular smooth muscle cells (SMC) play a critical role in plaque stabilization by
forming the fibrous cap that covers the lipid-laden plaque and necrotic core. Recent studies have revealed the
paradigm-changing findings that SMC comprise a greater portion of the plaque interior than previously
appreciated by transdifferentiating to phenotypes that lack SMC markers, and that investment of the
plaque by SMC-derived cells appears to be atheroprotective. Thus, SMC play a central role in regulating
both plaque size and stability.
Multiple lines of evidence support a protective role for TGF signaling in plaques. We have recently
identified the protein LIM Domain Only 7 (LMO7) as a key negative feedback regulator of TGF signaling in SMC
that promotes wound healing resolution (Xie et al, Circulation, 2019). Mice with global or inducible smooth
muscle-specific knockout of LMO7 (SM-LMO7-/-) exhibit enhanced TGF signaling and extracellular matrix
(ECM) synthesis compared to controls following vascular injury. We find that LMO7 represses the TGF pathway
at multiple levels. In new studies, we demonstrate that SM-LMO7-/- mice develop plaques of similar size but
with features of increased stability compared to controls in the ApoE-/- high fat diet (HFD) model. The SM-
LMO7-/- plaques have reduced necrotic core size, decreased CD68+ cells, increased ACTA2 and collagen
staining, and thicker fibrous caps. Preliminary lineage tracing data in these mice reveals that SM-LMO7-/-
increases the number of transdifferentiated SMC-derived cells in lesions, a phenotype that may be protective.
Preliminary data in human carotid specimens reveals that LMO7 mRNA expression is increased 5.6X in plaque
vs normal artery, and is enriched in ruptured vs non-ruptured lesions. We hypothesize that LMO7 loss of function
in SMC promotes more stable plaques in mice and humans. In Aim 1, we will determine the role of SMC LMO7
in plaque composition and gene expression using comprehensive staining and single cell RNA-sequencing
analyses. In Aim 2, we will dissect underlying mechanisms, and in Aim 3, we directly test the role of SMC LMO7
in lesion stability by assessing plaque rupture in mice, as well as LMO7 expression and localization in human
ruptured vs stable lesions. These studies will provide insights into the pathophysiology of atherosclerotic plaque
remodeling with potential therapeutic implications.
LMO 7在动脉粥样硬化中的作用动脉粥样硬化是心血管疾病发病率的主要原因,
死亡率,包括心肌梗死(MI)、卒中和外周血管疾病。由于斑块破裂是一种
作为动脉粥样硬化血栓事件的关键因素,了解斑块稳定性的决定因素至关重要。的
其潜在的分子机制知之甚少,但薄帽纤维粥样硬化,其特征在于
炎症、基质金属蛋白酶(MMP)活性、大的坏死核心和薄的纤维帽也被考虑在内
更容易破裂血管平滑肌细胞(SMC)在斑块稳定中起关键作用,
形成纤维帽,覆盖脂质斑块和坏死核心。最近的研究表明,
改变范式的发现,即SMC占斑块内部的比例比以前更大
通过转分化到缺乏SMC标记的表型来欣赏,并且对SMC的投资是通过对SMC的标记来实现的。
SMC衍生细胞的斑块似乎具有动脉粥样硬化保护作用。因此,SMC在调节
斑块大小和稳定性。
多种证据支持TGF β 1信号在斑块中的保护作用。我们最近
鉴定了蛋白质LIM结构域仅7(LMO 7)作为SMC中TGF β 1信号传导的关键负反馈调节剂
促进伤口愈合解决(Xie et al,Circulation,2019)。具有全局或诱导性光滑的小鼠
肌肉特异性敲除LMO 7(SM-LMO 7-/-)表现出增强的TGF β信号传导和细胞外基质
(ECM)合成相比,对照血管损伤后。我们发现LMO 7抑制TGF β通路,
在多个层面上。在新的研究中,我们证明了SM-LMO 7-/-小鼠产生类似大小的斑块,
在ApoE-/-高脂饮食(HFD)模型中,与对照相比具有增加的稳定性的特征。SM-
LMO 7-/-斑块具有减少的坏死核心尺寸、减少的CD 68+细胞、增加的ACTA 2和胶原蛋白
染色和较厚的纤维帽。这些小鼠中的初步谱系追踪数据显示,SM-LMO 7-/-
增加病变中转分化SMC衍生细胞的数量,这是一种可能具有保护作用的表型。
人颈动脉标本的初步数据显示,斑块中LMO 7 mRNA表达增加5.6倍,
相对于正常动脉,并且在破裂相对于非破裂病变中富集。我们假设LMO 7功能丧失
在SMC中促进小鼠和人类中更稳定的斑块。在目标1中,我们将确定SMC LMO 7的作用
在噬菌斑组成和基因表达中使用综合染色和单细胞RNA测序
分析。在目标2中,我们将剖析潜在的机制,在目标3中,我们直接测试SMC LMO 7的作用
通过评估小鼠中斑块破裂以及人中LMO 7表达和定位,
破裂vs稳定病变。这些研究将提供深入了解动脉粥样硬化斑块的病理生理学
具有潜在治疗意义的重塑。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kathleen Ann Martin其他文献
Kathleen Ann Martin的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Kathleen Ann Martin', 18)}}的其他基金
Vascular Discovery, From Genes to Medicine 2023
血管发现,从基因到医学 2023
- 批准号:
10683501 - 财政年份:2023
- 资助金额:
$ 56.8万 - 项目类别:
2022 Vascular Discovery: From Genes to Medicine
2022 年血管发现:从基因到医学
- 批准号:
10469131 - 财政年份:2022
- 资助金额:
$ 56.8万 - 项目类别:
Novel insights into intimal hyperplasia in cardiac allograft vasculopathy
对心脏同种异体移植血管病中内膜增生的新见解
- 批准号:
10090623 - 财政年份:2018
- 资助金额:
$ 56.8万 - 项目类别:
Epigenetic control of vascular smooth muscle in cardiovascular disease
心血管疾病中血管平滑肌的表观遗传控制
- 批准号:
8761918 - 财政年份:2014
- 资助金额:
$ 56.8万 - 项目类别:
Regulation of vascular smooth muscle cell plasticity
血管平滑肌细胞可塑性的调节
- 批准号:
8998052 - 财政年份:2014
- 资助金额:
$ 56.8万 - 项目类别:
Regulation of vascular smooth muscle cell plasticity
血管平滑肌细胞可塑性的调节
- 批准号:
8630004 - 财政年份:2014
- 资助金额:
$ 56.8万 - 项目类别:
Regulation of vascular smooth muscle cell plasticity
血管平滑肌细胞可塑性的调节
- 批准号:
8798690 - 财政年份:2014
- 资助金额:
$ 56.8万 - 项目类别:
Regulation of vascular smooth muscle cell plasticity
血管平滑肌细胞可塑性的调节
- 批准号:
9211370 - 财政年份:2014
- 资助金额:
$ 56.8万 - 项目类别:
相似国自然基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
- 批准号:LBY21H010001
- 批准年份:2020
- 资助金额:0.0 万元
- 项目类别:省市级项目
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
- 批准号:81703335
- 批准年份:2017
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
- 批准号:81670594
- 批准年份:2016
- 资助金额:58.0 万元
- 项目类别:面上项目
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
- 批准号:81470791
- 批准年份:2014
- 资助金额:73.0 万元
- 项目类别:面上项目
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
- 批准号:81301123
- 批准年份:2013
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
- 批准号:81101529
- 批准年份:2011
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
- 批准号:39500043
- 批准年份:1995
- 资助金额:9.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Development of an apoptosis biosensor for monitoring of breast cancer
开发用于监测乳腺癌的细胞凋亡生物传感器
- 批准号:
10719415 - 财政年份:2023
- 资助金额:
$ 56.8万 - 项目类别:
Milk fat globule-EGF factor 8 and hepatocyte apoptosis-induced liver wound healing response
乳脂肪球-EGF因子8与肝细胞凋亡诱导的肝脏创面愈合反应
- 批准号:
10585802 - 财政年份:2023
- 资助金额:
$ 56.8万 - 项目类别:
Interrogating the Fgl2-FcγRIIB axis on CD8+ T cells: A novel mechanism mediating apoptosis of tumor-specific memory CD8+ T cells
询问 CD8 T 细胞上的 Fgl2-FcγRIIB 轴:介导肿瘤特异性记忆 CD8 T 细胞凋亡的新机制
- 批准号:
10605856 - 财政年份:2023
- 资助金额:
$ 56.8万 - 项目类别:
Mechanistic analysis of apoptosis induction by HDAC inhibitors in head and neck cancer
HDAC抑制剂诱导头颈癌凋亡的机制分析
- 批准号:
23K15866 - 财政年份:2023
- 资助金额:
$ 56.8万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Novel targeted therapy for FGFR inhibitor-resistant urothelial cancer and apoptosis based therapy for urothelial cancer
FGFR抑制剂耐药性尿路上皮癌的新型靶向治疗和基于细胞凋亡的尿路上皮癌治疗
- 批准号:
23K08773 - 财政年份:2023
- 资助金额:
$ 56.8万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Interrogating the Fgl2-FcgRIIB axis: A novel mechanism mediating apoptosis of tumor-specific memory CD8+ T cells
探究 Fgl2-FcgRIIB 轴:介导肿瘤特异性记忆 CD8 T 细胞凋亡的新机制
- 批准号:
10743485 - 财政年份:2023
- 资助金额:
$ 56.8万 - 项目类别:
Investigating the role of apoptosis-resistance and the tumor environment on development and maintenance of sacrococcygeal teratomas
研究细胞凋亡抗性和肿瘤环境对骶尾部畸胎瘤发生和维持的作用
- 批准号:
10749797 - 财政年份:2023
- 资助金额:
$ 56.8万 - 项目类别:
The effects of glucose on immune cell apoptosis and mitochondrial membrane potential and the analysis of its mechanism by which glucose might modulate the immune functions.
葡萄糖对免疫细胞凋亡和线粒体膜电位的影响及其调节免疫功能的机制分析。
- 批准号:
22K09076 - 财政年份:2022
- 资助金额:
$ 56.8万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
XAF1 IN P53 SIGNALING, APOPTOSIS AND TUMOR SUPPRESSION
P53 信号传导、细胞凋亡和肿瘤抑制中的 XAF1
- 批准号:
10583516 - 财政年份:2022
- 资助金额:
$ 56.8万 - 项目类别:
Role of Thioredoxin system in regulation of autophagy-apoptosis cross talk in neurons: Uncovering Novel Molecular Interactions.
硫氧还蛋白系统在神经元自噬-凋亡串扰调节中的作用:揭示新的分子相互作用。
- 批准号:
RGPIN-2019-05371 - 财政年份:2022
- 资助金额:
$ 56.8万 - 项目类别:
Discovery Grants Program - Individual














{{item.name}}会员




